Đăng xuất
Oprymea is indicated in adults for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. throughout the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur.
Oprymea prolonged-release tablets are indicated for the symptomatic treatment of moderate to severe "Restless Leg Syndrome - RLS" in doses up to 0.75 mg as salt.
